BACKGROUND/AIMS: The apolipoprotein E (ApoE) exon 4 polymorphism has been associated with vascular dementia (VaD) risk. Since not all studies confirm this finding, we explored this association in a case-control study. METHODS: We genotyped ApoE in 144 VaD patients and 251 controls. RESULTS: VaD patients were more likely than controls to have ApoE epsilon3/epsilon4 or epsilon4/epsilon4 genotypes: 23.6% versus 15.1%, odds ratio (OR) = 1.7, p = 0.036. This association remained significant after adjustment for age, sex, hypertension and diabetes by multiple logistic regression: OR = 1.9, p = 0.030. The association of epsilon3/epsilon4 or epsilon4/epsilon4 genotypes with VaD was strong among people with hypertension (OR = 2.9, p = 0.007) or diabetes (OR = 6.5, p = 0.011). The association was absent among people without hypertension (OR = 1.1, p = 0.79) or diabetes (OR = 1.3, p = 0.43). CONCLUSION: This interaction with hypertension and diabetes should be examined in other studies to confirm or refute this observation. Copyright (c) 2006 S. Karger AG, Basel.
BACKGROUND/AIMS: The apolipoprotein E (ApoE) exon 4 polymorphism has been associated with vascular dementia (VaD) risk. Since not all studies confirm this finding, we explored this association in a case-control study. METHODS: We genotyped ApoE in 144 VaD patients and 251 controls. RESULTS: VaD patients were more likely than controls to have ApoE epsilon3/epsilon4 or epsilon4/epsilon4 genotypes: 23.6% versus 15.1%, odds ratio (OR) = 1.7, p = 0.036. This association remained significant after adjustment for age, sex, hypertension and diabetes by multiple logistic regression: OR = 1.9, p = 0.030. The association of epsilon3/epsilon4 or epsilon4/epsilon4 genotypes with VaD was strong among people with hypertension (OR = 2.9, p = 0.007) or diabetes (OR = 6.5, p = 0.011). The association was absent among people without hypertension (OR = 1.1, p = 0.79) or diabetes (OR = 1.3, p = 0.43). CONCLUSION: This interaction with hypertension and diabetes should be examined in other studies to confirm or refute this observation. Copyright (c) 2006 S. Karger AG, Basel.
Authors: Rosebud O Roberts; Ruth H Cha; Michelle M Mielke; Yonas E Geda; Bradley F Boeve; Mary M Machulda; David S Knopman; Ronald C Petersen Journal: Neurology Date: 2015-04-08 Impact factor: 9.910
Authors: Yi-Fang Chuang; Kathleen M Hayden; Maria C Norton; Joann Tschanz; John C S Breitner; Kathleen A Welsh-Bohmer; Peter P Zandi Journal: Dement Geriatr Cogn Disord Date: 2010-04-06 Impact factor: 2.959
Authors: H Qureischie; R Heun; J Popp; F Jessen; W Maier; S Schmitz; F Hentschel; P Kelemen; H Kölsch Journal: J Neural Transm (Vienna) Date: 2009-01-28 Impact factor: 3.575